Fennec Pharmaceuticals Inc (NASDAQ:FENC) COO Adrian Haigh Sells 22,222 Shares

Fennec Pharmaceuticals Inc (NASDAQ:FENC) COO Adrian Haigh sold 22,222 shares of Fennec Pharmaceuticals stock in a transaction dated Monday, April 15th. The stock was sold at an average price of $10.30, for a total transaction of $228,886.60. Following the completion of the transaction, the chief operating officer now directly owns 22,222 shares of the company’s stock, valued at $228,886.60. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Fennec Pharmaceuticals Trading Down 5.5 %

Shares of NASDAQ FENC opened at $9.70 on Thursday. The firm has a 50 day moving average of $10.10 and a 200 day moving average of $9.33. The firm has a market capitalization of $262.87 million, a price-to-earnings ratio of -15.90 and a beta of 0.38. Fennec Pharmaceuticals Inc has a 12-month low of $6.30 and a 12-month high of $11.92.

Fennec Pharmaceuticals (NASDAQ:FENC) last announced its earnings results on Thursday, March 21st. The company reported ($0.10) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.02 by ($0.12). The company had revenue of $9.74 million for the quarter, compared to the consensus estimate of $9.47 million. Sell-side analysts predict that Fennec Pharmaceuticals Inc will post 0.11 EPS for the current year.

Analyst Upgrades and Downgrades

FENC has been the subject of a number of research analyst reports. Craig Hallum lifted their price target on shares of Fennec Pharmaceuticals from $17.00 to $18.00 and gave the stock a “buy” rating in a research note on Monday, March 18th. HC Wainwright lifted their price target on shares of Fennec Pharmaceuticals from $17.00 to $18.00 and gave the stock a “buy” rating in a research note on Thursday, April 4th. Finally, Wedbush reiterated an “outperform” rating and issued a $16.00 price target on shares of Fennec Pharmaceuticals in a research note on Monday, March 18th.

Institutional Trading of Fennec Pharmaceuticals

Several large investors have recently added to or reduced their stakes in the business. Royal Bank of Canada grew its position in Fennec Pharmaceuticals by 21.1% during the fourth quarter. Royal Bank of Canada now owns 7,102 shares of the company’s stock valued at $79,000 after buying an additional 1,236 shares during the period. Tower Research Capital LLC TRC boosted its position in shares of Fennec Pharmaceuticals by 107.3% in the fourth quarter. Tower Research Capital LLC TRC now owns 3,048 shares of the company’s stock worth $34,000 after purchasing an additional 1,578 shares during the period. Citigroup Inc. boosted its position in shares of Fennec Pharmaceuticals by 10.3% in the first quarter. Citigroup Inc. now owns 18,590 shares of the company’s stock worth $151,000 after purchasing an additional 1,742 shares during the period. Vanguard Group Inc. boosted its position in shares of Fennec Pharmaceuticals by 2.4% in the third quarter. Vanguard Group Inc. now owns 81,768 shares of the company’s stock worth $614,000 after purchasing an additional 1,895 shares during the period. Finally, Hartford Financial Management Inc. boosted its position in shares of Fennec Pharmaceuticals by 4.4% in the fourth quarter. Hartford Financial Management Inc. now owns 47,348 shares of the company’s stock worth $531,000 after purchasing an additional 2,000 shares during the period. 55.51% of the stock is currently owned by institutional investors.

Fennec Pharmaceuticals Company Profile

Fennec Pharmaceuticals Inc, a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children.